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Abstract BRCA2 and PALB2 function together in the
Fanconi anemia (FA)–Breast Cancer (BRCA) pathway.
Mono-allelic and bi-allelic BRCA2 and PALB2 mutation
carriers share many clinical characteristics. Mono-allelic
germline mutations of BRCA2 and PALB2 are risk alleles
of female breast cancer and have also been reported in
familial pancreatic cancer, and bi-allelic mutations cause a
severe form of Fanconi anemia. In view of these similari-
ties, we investigated whether the prevalence of PALB2
mutations was increased in breast cancer families with the
occurrence of BRCA2 associated tumours other than female
breast cancer. PALB2 mutation analysis was performed in
110 non-BRCA1/2 cancer patients: (a) 53 ovarian cancer
patients from female breast-and/or ovarian cancer families;
(b) 45 breast cancer patients with a first or second degree
relative with pancreatic cancer; and (c) 12 male breast
cancer patients from female breast cancer families. One
truncating PALB2 mutation, c.509_510delGA, resulting in
p.Arg170X, was found in a male breast cancer patient. We
conclude that germline mutations of PALB2 do not sig-
nificantly contribute to cancer risk in non-BRCA1/2 cancer
families with at least one patient with ovarian cancer, male
breast cancer, and/or pancreatic cancer.
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Introduction
Breast cancer (BC) is a major cause of cancer-related
deaths among women. At present, 20% of familial breast
cancer is explained by germline mutations in known breast
cancer predisposition genes. The high risk breast cancer
susceptibility genes BRCA1 and BRCA2 account for the
majority of these causative mutations [1]. Heterozygous
BRCA1 mutation carriers are at high risk of female breast
cancer and ovarian cancer. Heterozygous BRCA2 mutation
carriers are at high risk of female breast cancer, and several
other cancers. Estimated cumulative risks from several
studies varies in BRCA2 female carriers from 14–24% for
ovarian cancer, and 3% for pancreatic cancer [2, 3]. In
male BRCA2 carriers, cancer risk is estimated around 6–7%
for pancreatic cancer and male breast cancer [2, 3].
One of the pathways often involved in breast cancer
susceptibility is the Fanconi anemia (FA)–Breast Cancer
(BRCA) pathway [4]. At present, 13 FA genes have been
identified. FA is an autosomal recessive or X-linked
inherited disorder with hypersensitivity to DNA cross-
linking agents and chromosomal instability at the cellular
level. Clinically FA is characterized by congenital mal-
formations, bone marrow failure and predisposition to
cancer, primarily acute myeloid leukemia and squamous
cell carcinoma.
BRCA2 and PALB2 are two of the currently known FA
genes. PALB2 (FANCN), which is named to its function as
a partner and localizer of BRCA2 (FANCD1) [5–7]. PALB2
has been shown to enable the BRCA2 protein to function in
DNA repair by stabilization in nuclear foci [8].
BRCA2 and PALB2, also share additional clinical fea-
tures, namely an increased risk to childhood solid tumours
in bi-allelic mutation carriers and an increased risk to
female breast cancer (RR of 8–10 and 2, respectively) and
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pancreatic cancer in mono-allelic mutation carriers [1, 7, 9,
10].
In view of the overlapping phenotype and function of
BRCA2 and PALB2, we hypothesized that PALB2 muta-
tions may preferentially associate with BRCA1/2 negative
tested cancer families with a BRCA2-like cancer pheno-
type, namely families in which BRCA2-associated tumours
other than female breast cancer are observed. We screened
PALB2 in a cohort of 110 cancer patients from non-
BRCA1/2 families selected for ovarian cancer, pancreatic
cancer and male breast cancer.
The prevalence of PALB2 mutations was low in our
enriched non-BRCA1/2 cohort since only one truncating
mutation was found.
Materials and methods
Cohort
A total of 110 cases from independent families referred to
the clinical genetics department of the VU Medical Center
in Amsterdam between 1994 and 2008 were analysed for
PALB2 mutations and large deletions. All cases were
excluded for mutations in BRCA1 and BRCA2 genes.
Individuals with a BRCA2 associated tumour were selected
for this study on the basis of being affected with: (a)
ovarian cancer (n = 53) with a family history of female
breast-and/or ovarian cancer (age at diagnosis of ovarian
cancer ranged from 22–76 years, average 54 years), (b)
female breast cancer with a first or second degree relative
with pancreatic cancer (n = 45, age at diagnosis of breast
cancer ranged from 23–74 years, average 43 years) and (c)
male breast cancer with a family history of female breast
cancer (n = 12, age at diagnosis of male breast cancer
ranged from 32–77 years, average 54 years).
Of the 53 women with ovarian cancer, 16 had a personal
history of both ovarian cancer and breast cancer. Of the 45
breast cancer cases, eight were bilaterally affected.
Mutation carrier probability in our cohort was scored
with two manual BRCA1/2 risk assessment models. Of our
selected cases, 60 and 39% scored a C15% and C20%
probability of being carrier of a BRCA1/2 mutation
according to Myriad II (Frank model), respectively
(www.myriadtests.com). Since this model does not account
for relatives with breast cancer above 50 and/or relatives
with pancreatic cancer, we also scored the families with the
Manchester model, which appears to be more predictive for
BRCA2 mutations [11]. The total Manchester score was
C15 or C20 in 72 and 43% of the selected families,
respectively.
All cases gave informed consent to search for new
cancer susceptibility genes.
Sequencing and MLPA
The presence of germline mutations in PALB2 was evalu-
ated by direct sequencing of the entire coding region and
intron–exon boundaries on genomic DNA isolated from
whole blood. Primer pairs that were used have been pre-
viously described [6].
To determine the segregation of the c.509_510delGA
mutation in the family, a nested PCR within exon 4 of
PALB2 was performed using the following forward (F) and
reverse (R) primer sequences surrounding the mutation; F
50-GAA GCA GCA GAA GAG GAC AT-30 and R 50-TTC
AGT TAC TGG TGA TCT AGC-30. DNA was isolated
from whole blood from one sister, and DNA was isolated
from paraffin embedded normal and tumour tissue from the
deceased sister (Fig. 1).
The presence of large deletions in the PALB2 gene was
analyzed by Multiplex Ligation-dependent Probe Amplifi-
cation (MLPA) using the MLPA P057 kit of MRC-Holland
as previously described [12]. As a positive control, geno-
mic DNA from the previously described PALB2 FA patient
EUFA1341 was included in the analysis [6].
All coding exons (including intron/exon boundaries) of
BRCA1 and BRCA2 were screened for mutations by a
combination of denaturing gradient gel electrophoresis and
DNA sequencing. In addition, BRCA1 was tested for exon
deletions and duplications by MLPA.
Results
Sequence analysis of the PALB2 gene in a selected cohort
of 110 non-BRCA1/2 cases (for selection see Materials and
Methods) revealed a frameshift mutation in exon 4,
c.509_510delGA. The mutation is predicted to result in
p.Arg170X at the protein level and was identified in one of
the male breast cancer cases (Fig. 1). The male patient had
breast cancer and a melanoma in situ, both at age 62 years.
The breast cancer was a grade 3 invasive ductal carcinoma,
which was positive for Estrogen (ER) and Progesteron
(PR), and negative for Her2. He died at the age of 64 years.
The melanoma in situ was located on his back.
The PALB2 mutation was not present in DNA isolated
from paraffin-embedded tumour and normal breast tissue
from the deceased sister with lobular breast cancer (ER
negative, PR negative and Her2 positive). DNA of the
mother and one of the affected sisters with breast cancer
was not available. Although not considered as a BRCA-
associated tumour, we did test whole blood DNA from the
sister with uterine carcinoma at age 77 years. She did not
carry the mutation either.
Seven different amino acid substitutions were found. All
are known SNP’s and six have been previously described to
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occur frequently and in equal percentages in affected breast
cancer cases and controls [13]. One of these variants, the
L939W, is predicted (although with low confidence) to
possibly affect the protein function in three in silico tests
(PolyPhen, SIFT and align GVGD). However, this variant
was found in three previous studies including the large
breast cancer case control study by Rahman et al. [13–15].
Therefore all missense variants are unlikely to have a
significant pathogenic effect (Table 1). Intronic and syn-
onymous variants which are not predicted to affect splicing
are unlikely to have any clinical relevance (Table 1).
The cohort was also analyzed for larger deletions using
MLPA in PALB2. No alterations in the PALB2 gene were
identified by MLPA in any of the 110 cases.
Discussion
The chance of finding a cancer predisposing allele generally
increases when families harbour increasing numbers of
patients, or multiple phenotypes associated with the risk
allele. For example the mutation rate in the high risk breast
cancer predisposing genes BRCA1 and BRCA2 increases
dramatically in an individual when multiple cases of early
onset breast cancer, or additionally ovarian cancer occurs
within the family (www.myriadtests.com). Likewise, for the
low risk breast cancer predisposing allele CHEK2*1100-
delC the chance of finding this allele increases from 1, 3, to
5–6% in the Dutch population, in sporadic breast cancer, and
in familial breast cancer or in bilateral breast cancer [16, 17].
Statistical modelling showed that this was best explained by
a polygenic model in which multiple low risk alleles
increased cancer risk in a multiplicative way [16].
We therefore hypothesized that the frequency of muta-
tions in the moderate risk breast cancer predisposing gene
PALB2 may increase in case additional cancer phenotypes
are present within the family.
We screened a cohort of 110 non-BRCA1/2 cancer
patients, including 53 ovarian cancer patients, 45 female
breast cancer patients with a first or second degree relative
with pancreatic cancer and 12 male breast cancer patients,
for the presence of truncating mutations in the PALB2 gene
by sequencing and MLPA analysis. Direct sequencing
revealed one truncating mutation (p.Arg170X) in a male
breast cancer patient, which was not present in DNA from
one sister with breast cancer and in the sister with uterine
cancer (Fig. 1).
MLPA did not detect any deletion in our cohort. Pre-
viously we already described that exon deletions and
duplications in PALB2 were not observed in a large cohort
of Dutch familial breast cancer patients [12].
The PALB2 mutation frequency in this enriched cohort
with BRCA2 associated tumours was not increased when
compared to the described prevalence of approximately 1%
in familial non-BRCA1/2 breast cancer cohorts [13, 14, 18].
Currently, there is evidence that PALB2 is involved in
predisposition to breast cancer and familial pancreatic
cancer, but this is lacking for other cancers, in particular
male breast cancer and ovarian cancer.
In total, 77 PALB2 mutation-positive cases have been
identified mainly in familial or early onset breast cancer
cohorts from different populations [13, 15, 18–25]. Of the
77 described PALB2 mutation cases, 52 are carrier of the
1592delT Finnish founder mutation, which could influence
the currently known phenotype [19, 24, 26]. The selection
criteria of these previous breast cancer studies varied, but
most studies included BRCA1/2 mutation negative early
onset breast cancer patients with diagnosis under 50 years
or breast cancer patients from families with first or second
degree relatives affected with breast-or ovarian cancer in
unknown numbers.
Ovarian cancer is the most prevalent cancer type in
BRCA2 mutated families next to breast cancer. Our cohort
included 53 familial ovarian cancer patients, but no
mutation was found in PALB2 in any of these cases.
d86 BC85 Prostate
d61
d72 d86
d83 BC61 right
BC77 left
BC57
-/-
BC62
Melanoma in situ 62
BRCA1/2 -
+/-
BC58
Ovarian?
d62
Uterine 77
-/-
Fig. 1 Pedigree of the family
with the c.509_510delGA
PALB2 mutation. In black are
the individuals affected with
cancer; arrow indicates the
patient with the
c.509_510delGA mutation. The
mutation carrier was BRCA1/2
negative tested. Cancer type
(BC breast cancer), side and age
of cancer diagnosis or if
unknown age of death (d) is
mentioned below the
individuals. Tested individuals
were marked with -/- for wild
type (WT) or ?/- for mono-
allelic mutation carrier
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Recently, a Polish study tested a set of sporadic 70
ovarian carcinomas for PALB2 mutations [27]. Remarkably
they found the same mutation (c.509_510delGA) as we did.
After this finding, they analyzed additional cohorts for the
prevalence of the c.509_510delGA mutation: a cohort of
339 unselected tumour fragments of ovarian carcinomas; a
cohort of 982 breast cancer patients, of which 648 familial
cases; and 1310 controls. They identified this mutation in 2
out of 339 ovarian cancers (0.6%), 4 out of 982 breast
cancers (0.4%; all familial cases), and 1 out of 1,310
controls (0.08%). One of the ovarian cancer patients
appeared to carry a pathogenic BRCA2 mutation. Most of
the cancer cases included in this study were not or only
partially analyzed for mutations of BRCA1 and BRCA2.
Since the c.509_510delGA mutation was recurrently found
in the Polish population, it was suggested to be a possible
PALB2 founder mutation in central Poland. Till now all
mutations, except the Finnish PALB2 founder mutation,
were unique. We identified the c.509_510delGA mutation
in a male breast cancer patient from Dutch ancestry. The
Table 1 Variants identified in PALB2/FANCN
PALB2 cDNA change Protein
change
SNP Number
found
Prediction programs
Polyphen SIFT AGVGD
m1 c.509_510delGA p.Arg170X 1
as1 c.194C[T p.Pro65Leu rs62625272 1 Possibly
damaging
Tolerated Less likely (C0)
as2 c.1010T[C p.Leu337Ser rs45494092 6 Possibly
damaging
Affect
protein
function
Less likely (C0)
as3 c.1676A[G p.Gln559Arg rs152451 26 Benign Tolerated Less likely (C0)
as4 c.2014G[C p.Glu672Gln rs45532440 9 Benign Affect
protein
function
Less likely (C0)
as5 c.2590C[T p.Pro864Ser rs45568339 1 Probably
damaging
Tolerated Less likely (C0)
as6 c.2816T[G p.Leu939Trp rs45478192 1 Possibly
damaging
Affect
protein
function
Likely (C55)
as7 c.2993G[A p.Gly998Glu rs45551636 6 Probably
damaging
Affect
protein
function
Less likely (C0)
syn1 c.1470C[T p.= rs45612837 1
syn2 c.1572A[G p.= rs45472400 3
syn3 c.3300T[G p.= rs45516100 8
Non-coding
ip1 c.-47 G[A rs8053188 5
ip2 c.3114-51T[A rs249936 110
ip3 c.3201?101A[G rs249935 26
ip4 c.2586?58C[T rs249954 51
ip5 c.2996?264T[C rs420259 56
iv1 c.-145 G[C 1
iv2 c.2749-18C[T 2
iv3 c.3201?95C[T 8
iv4 c.212-58A[C 4
iv5 c.1684?37_1684?39del 1
iv6 c.2996?17T[C 1
m mutation, as amino acid substitution, syn synonymous variant, ip intronic polymorphism, iv intronic variant, SNP is a single nucleotide
polymorphism. Nomenclature according to the Human Genome Variation Society (HGVS) recommendations (www.hgvs.org). Pathogeneity of
missense variants was predicted using 3 in silico tests; Polymorphism Phenotyping (PolyPhen) prediction (http://genetics.bwh.harvard.edu/pph);
Sorting Intolerant From Tolerant (SIFT) (http://blocks.fhcrc.org/sift/SIFT.html) and align GVGD (http://agvgd.iarc.fr). According to the splice
site prediction algorithms incorporated in Alamut version 1.5 (SpliceSiteFinder-like, MaxEntScan, NNSPLICE and GeneSplicer) no evidence
was found for splice defects caused by the non-coding intronic variants
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c.509_510delGA mutation may therefore either represent a
recurrent mutation or a founder mutation with a much
larger geographical distribution than central Poland.
The data of this Polish study and our data suggest that
PALB2 has only a marginal role in ovarian cancer
predisposition.
Pancreatic cancer risk related to PALB2 was evaluated
in familial (n = 197) and in sporadic pancreatic cancer
cases (n = 114) [10, 28]. In total, five PALB2 mutation
carriers with pancreatic cancer were identified. All but one
of these five families were also affected with breast cancer
and the only two female PALB2 mutation carriers both
suffered from pancreatic cancer and breast cancer. We
analyzed 45 breast cancer patients with a first or second
degree relative with pancreatic cancer. However, no trun-
cating mutation was found.
The only truncating mutation (p.Arg170X) in our cohort
was found in one out of 12 male breast cancers patients.
This confirms the results of a previous breast cancer study
in which one out of 15 female breast cancer patients with
male breast cancer in the family contained a mutation
(6.7%) [13]. Three previous studies have reported on the
frequency of PALB2 mutations in male breast cancer. In
141 unselected Finnish male patients, the Finnish PALB2
founder mutation was not found [19]. The whole coding
sequence of PALB2 was analyzed in 25 Australian male
breast cancer cases from breast cancer families, and in 97
BRCA1/2 negative male breast cancer cases from Italy, of
which 26% had a positive family history of breast and/or
ovarian cancer in a first degree relative. No truncating
mutations were found in either study [29, 30].
Overall, these data do not suggest a significant relation
of PALB2 mutations and male breast cancer.
With respect to various other cancers, the Finnish
PALB2 founder mutation was tested in two independent
studies including in total 476 unselected colorectal cancer
cases, 1223 unselected prostate cancer cases, and 342
familial prostate cancer cases [19, 26]. Two familial and
two unselected prostate cancer cases carried the founder
mutation (0.6 and 0.16% respectively). Of note, the fre-
quency of the Finnish PALB2 founder mutation is 0.2% in
the general (Finnish) population. Tischkowitz et al.
sequenced PALB2 in 95 prostate cancer families from
American descent and found no truncating mutations [31].
Overall, these data suggest that these cancer types are not
significantly associated with mutations in PALB2. Cancer
types that are still disputed to be associated with BRCA2,
like prostate cancer, colonic cancer, melanoma, and
stomach cancer were left out of our cohort.
To conclude there is no enrichment for the prevalence of
germline heterozygous PALB2 mutations in familial non-
BRCA1/2 ovarian cancer patients, breast cancer patients
with a familial history of pancreatic cancer, and familial
non-BRCA1/2 male breast cancer patients. Therefore
diagnostic testing of PALB2 in non-BRCA1/2 families is
not indicated in these settings.
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